HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

NEXT STORY
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
PREV STORY
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

author_avatar
NASDAQ Market News

American BriVision Announces Postponement of Proposed Public Offering

author_avatar
NASDAQ Market News

Changes to the Nomination Committee for Immunicum AB (publ)

Press Release 30 January 2019 Changes to the Nomination Committee for Immunicum AB (publ) ...

author_avatar
NASDAQ Market News